Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients

BackgroundEnd-stage kidney disease substantially increases the risk of severe COVID-19. However, despite early robust immunogenicity of the mRNA-SARS-CoV-2 vaccination in patients with hemodialysis, the longevity of humoral response in this high-risk population is still unknown.MethodsA prospective...

Full description

Bibliographic Details
Main Authors: Timna Agur, Naomi Ben-Dor, Michal Herman-Edelstein, Tali Steinmetz, Shelly Lichtenberg, Shira Schneider, Dafna Yahav, Benaya Rozen-Zvi, Boris Zingerman
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Medicine
Subjects:
COVID-19
SARS-COV-2
hemodialysis
BNT162b2
anti-spike antibody
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.781888/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.781888/full

Similar Items